The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030, predicts Roots Analysis


Posted January 28, 2021 by kevinKD123-123_123

An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019.
 
Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access



Roots Analysis is pleased to announce the publication of its recent study, titled, “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”



The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

A detailed review of the overall landscape of the non-invasive cancer diagnostics market. 
An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019.
An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics.
An analysis of the initiatives of big pharma players.
A detailed acquisition target analysis.
Elaborate profiles of the key players engaged in this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Tumor Marker
ctDNA
cfDNA
CTCs
Exosomes
Others


Application
Diagnosis / Early Diagnosis
Patient Monitoring
Recurrence Monitoring


Target Cancer Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Bladder Cancer
Melanoma
Gastric Cancer
Pancreatic Cancer
Ovarian Cancer
Others


End Users
Hospitals
Research Institutes
Others


Key Geographical Regions 




North America
Europe
Asia-Pacific
Rest of the World


Key companies covered in the report:

Amoy Diagnostics
DiaCarta
HaploX Biotechnology
NeoGenomics
QIAGEN
Swift Biosciences
Sysmex Inostics
Thermo Fisher Scientific


For more information, please click on the following link: 

https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html



Other recent offerings

Companion Diagnostics Market (2nd Edition), 2019-2030
Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030
Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030


About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]



Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Roots Analysis
Country American Samoa
Categories Biotech , Health , Industry
Tags healthcare , market research , wellness and fitness
Last Updated January 28, 2021